Moderne Therapie der Sarkoidose

A. Gillissen; S. Pietrzak

doi:10.1055/s-0032-1310104

Pneumologie, Table of Contents

Pneumologie 2012; 66(09): 539-546
DOI: 10.1055/s-0032-1310104

Fort- und Weiterbildung

Moderne Therapie der Sarkoidose

Modern Treatment of Sarcoidosis

Authors

A. Gillissen

Klinik für Lungen- und Bronchialmedizin, Klinikum Kassel
S. Pietrzak

Klinik für Lungen- und Bronchialmedizin, Klinikum Kassel

Abstract

Full Text

References

Literatur
1 Behr J, Costabel U. Interstitielle Lungenerkrankungen – historische Entwicklung, Status quo und Ausblick. Pneumologie 2010; 64: 573-576
2 Baughman RP, Nagai S, Balter M et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 56-64
3 Pabst S, Skowasch D, Grohé C. Sarkoidose. Pneumologie 2012; 66: 96-110
4 Kirsten D, Costabel U. Pulmonale Sarcoidose. Pneumologie 2005; 59: 378-394
5 Prasse A, Müller-Quernheim J. Sarcoidose. Internist 2009; 50: 581-590
6 Grohé C, Pabst S, Baumgarten G et al. Toll-like receptor (TLR) 4 Asp229Gly and Thr399ILe polymorphisms are associated with a chronic progressive course of pulmonary sarcoidosis. Clin Exp Immunol 2006; 143: 420-426
7 Hofmann S, Fischer A, Till A et al. A genemone-wide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Respir J 2011; 38: 122-129
8 Zissel G, Prasse A, Müller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010; 31: 390-403
9 Müller-Quernheim J, Schürmann M, Hofmann S et al. Genetik der Sarkoidose: Ein Schlüssel zum Verständnis ihrer Pathogenese. Pneumologie 2009; 63: 166-175
10 Chen ES, Moller DR. Sarcoidosis – scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7: 457-467
11 Constantino T, Digre K, Zimmerman P. Neuro-ophthalmic complications of sarcoidosis. Semin Neurol 2000; 20: 123-137
12 Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997; 112: 220-228
13 Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001; 18: 56s-68s
14 British Thoracic Society and Standards of Care Committee. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999; 54: 1-28
15 Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J 1999; 14: 735-737
16 Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29: 533-548
17 Gottlieb JE, Israel HL, Steiner RM et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631
18 Deutsche Gesellschaft für Pneumologie (DGP). Empfehlungen zur Diagnostik und Therapie der Sarkoidose. Pneumologie 1998; 52: 26-30
19 Wiegand JA, Brutsche M. Sarcoidosis is a multisystem disorder with variable prognosis – information for treating physicians. Swiss Med Wkly 2006; 136: 201-209
20 Wells AU, Hirani N. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zeeland and the Irish Thoracic Society. Thorax 2008; 63: 1-58
21 Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 2001; 13: 84-91
22 Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; 2 CD001114
23 Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Eur Respir J 1995; 8: 682-688
24 Coker RK. Guidelines for the use for corticosteroids in the treatment of pulmonary sarcoidosis. Drugs 2007; 67: 1139-1147
25 Bradley B, Branley HM, Egan JJ et al. Interstitital lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: 1-58
26 Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010; 31: 501-518
27 Baughman RP, Nunes D. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012; 8: 95-103
28 Sweiss NJ, Lower EE, Korsten P et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep 2012; 13: 265-272
29 Vucinic V, Skodric-Trifunovic V, Ignjatovic S. How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidencebased review. Curr Opin Pulm Med 2011; 17: 297-302
30 Pfeilschifter J (Hrsg). Die Leitlinien des Dachverbandes Osteologie zur Osteoporose. 1. Ausg. Bern: AZ Druck und Datentechnik GmbH; 2003
31 Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005; 4: 723-730
32 Raghu G, DePaso WJ, Cain K et al. Azathioprine combined with prednisolone in the treatment of idipathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296
33 Baltzan M, Mehta S, Kirkham TH et al. Randomized trial of prolonged cholorquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-197
34 Paramothayan NS, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2006; 3 CD003536
35 Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802
36 Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009; 14: 522-528
37 Judson MA, Baughman RP, Costabel U et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196
38 Loza MJ, Brodmerkel C, du Bois RM et al. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunology 2011; 18: 931-939
39 Hostettler KE, Studler U, Tamm M et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83: 218-224
40 Skoje IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int 2012; 32: 1049-1053
41 Zabel P, Entzian P, Dalhoff K et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669
42 Park MK, Fontana Jr, Babaali H et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 121-131
43 Bachelez H, Senet P, Cadranel J et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137: 69-73
44 Christie JD, Edwards LB, Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report 2008. J Heart Lung Transplant 2008; 27: 957-969